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ABSTRACT: 
This paper reviews some recent advances in our understanding of the effects of sham or 
dummy interventions on pain and other symptoms in osteoarthritis, and outlines two new 
approaches to the investigation of placebo and nocebo effects.  
We argue that the placebo effect provides us with a valuable way of investigating the nature 
of conditions like osteoarthritis (OA).  For example, by examining which symptoms, 
biochemical markers or imaging features do or do not respond to placebo, we might learn 
more about the relationships between pathology and symptoms in OA. 
Placebo and nocebo effects are positive or negative outcomes resulting from the human 
interactions and contexts in which healthcare consultations take place.  Subtle changes in 
behaviours and the environments in which consultations take place can have major effects on 
pain and other symptoms being experienced by people with OA.  Nocebo effects are 
particularly powerful, leading to many health-care professionals causing unintended harm to 
their clients. 
Based on our own research, we conclude that beneficial outcomes are most likely to occur 
when both the health-care professional and the client feel safe and relaxed, and when the 
experiences of the client are validated by the health-care professional.  These findings have 
important implications for clinical practice. 
We believe that research in this field needs to be ‘trans-disciplinary’, escaping from the 
constraints of the purely biomedical, deterministic, positivist paradigm of most medical 
research.  We provide the example of our own work which combines performance studies 
and scholarship, with psychology and medicine. 
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The power and value of placebo and nocebo in painful osteoarthritis 
 
Introduction: 
The placebo response is generally described as the improvement in health status that occurs 
with the administration of a sham intervention [1,2].  Following the uptake of the randomised 
controlled trial (RCT) as the central method for assessing the efficacy of interventions, it 
became commonplace to contrast the effect of a therapy that was targeting a particular 
problem (such as pain) with a sham therapy, as identical as possible to the ‘real’ one. This 
resulted in the trials-based definition of the placebo response.  But, as pointed out recently, 
the idea that placebo is about a sham treatment is misleading and unhelpful [2]. 
Some authors have questioned whether the placebo effect exists, as improvement with no 
active intervention could occur for other reasons, such as regression to the mean [3, 4].  Yet 
we believe that phenomena termed ‘placebo’ offer a rich source of data, and suggest that 
better understanding, and clearer delineation of terms, could enable their beneficial use.  As 
suggested by Kirsch [5], we separate placebo responses from placebo effects.  As shown in 
Figure 1, the placebo response is the change seen in response to a sham intervention, whereas 
the placebo effect is the difference in response between doing nothing (a no-treatment control 
group), and giving ‘nothing’ (giving a sham treatment that should do nothing). 
In this article, we concentrate on the placebo effect rather than response. We focus on 
changes in health status occurring after a health-care consultation involving no administration 
of a specific drug or other medical intervention.  We are not concerned with trials, rather our 
interest is in the contextual factors [6, 7] that can allow people to improve as a result of an 
encounter with a health-care professional (HCP) even if no specific therapy is used. 
This article is based on extensive primary and secondary research by a multi-disciplinary 
team that includes a doctor with an interest in OA (PD) a humanities scholar (SG) and a 
psychologist (M G-H), who have been working together on this topic for the last 5 years.  It is 
split into two parts; first we review some of what is known about the importance of placebo 
and nocebo effects and their mode of action, with an emphasis on pain in OA, secondly we 
describe the different research approaches that we are using to investigate the topic further, 
which emphasise client-practitioner interactions. 
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PART 1: Placebo and Nocebo Effects 
 
The placebo effect appears to be particularly important in the relief of symptoms such as pain 
and depression [1, 2, 8, 9]. But sham interventions and encounters with HCPs can do harm as 
well as good, a phenomenon called the nocebo effect [10]. Nocebo reactions have been noted 
to worsen both pain and anxiety [11, 12].  Pain, anxiety and depression are amongst the most 
important symptoms occurring in people with osteoarthritis (OA) [13]; this article will 
concentrate on pain, the dominant symptom for most people, but almost everything we say 
about pain and placebo/nocebo could also apply to anxiety and/or depression, and to other 
common symptoms and chronic disorders.   
 
The efficacy and effectiveness of placebo on pain in OA 
The efficacy of an intervention describes the changes that occur when the treatment is used in 
the artificial test conditions of a RCT.  Effectiveness refers to the changes that occur when 
that treatment is used in routine clinical care [14].  Efficacy demonstrated in a trial may not 
translate into effectiveness because of the influence of numerous context-related effects.  
Efficacy is often calculated and presented as the effect size of an intervention, which is the 
difference between the standardised mean effects of the intervention compared to that of no 
intervention. 
It has been possible to calculate the effect size of placebos in OA trials, because an 
examination of the literature uncovered enough RCTs that included a no-treatment control 
group to allow a valid statistical comparison of the effects of dummy treatments to no 
treatments. Zhang et al [15] found that the effect size of placebo for pain in OA was 0.51 
(95% confidence intervals 0.46-0.55) in comparison with 0.03 (+/- -0.13 - 0.18) for untreated 
control groups.  An effect size of 0.5, or thereabouts, is of considerable clinical value, and 
comparable to that of many of our commonly used interventions [16].  The same group 
published a further analysis, in which they used random-effects modelling to calculate the 
amount of pain relief that could be attributed to placebo (contextual) effects, and how much 
to the treatment being tested for its effects on pain in OA [17].  They report that on average 
75% of the overall treatment effect is due to the contextual factors rather than the specific 
intervention.   Another recent review used a network meta-analysis technique to synthesise 
data from 149 RCTs of adults with knee OA in which placebos were used [18].  The findings 
confirmed the power of placebo in OA, and also showed clearly, as reported in the 
aforementioned papers, that ‘all placebos are not equal’: intra-articular and topical sham 
therapies were superior to oral treatments in pain control.  Sham surgical interventions can 
also result in a great deal of pain relief [19].  This work suggests that we need to take more 
account of contextual factors when trying to interpret clinical trials in OA. 
The effectiveness of placebo in OA is unknown, as no large-scale pragmatic trials of sham 
treatment, or of a purely context-based intervention, compared with no treatment control 
groups have been undertaken.  However, it seems likely that the effectiveness of placebo for 
pain relief in OA can be considerably larger than its efficacy.  The artificial conditions of a 
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trial constrain the extent to which context effects and the behaviours of clinicians, thought to 
be crucial to the placebo effect [2,6,7], can be used to enhance the value of an intervention.  
Conversely, an appropriate consultation, within a safe environment, as explained below, 
could greatly enhance the effects of an intervention. 
Recent trials indicate that consultation style can enhance the size of a placebo response in OA 
and other chronic disorders.  In one study comparing Traditional Chinese Acupuncture 
(TCA) to sham acupuncture in patients with OA of the knee, no difference between the TCA 
and sham acupuncture was found, but the consultation style used by the acupuncturists made 
a big difference to outcomes [20]. A secondary analysis of the data suggested that the 
communication of optimism about likely outcomes led to a greater degree of pain relief [21]. 
A similar study has been undertaken in irritable bowel syndrome [22], and secondary analysis 
of the data from that study indicates not only that communication styles matter, but suggests 
that some practitioners obtain good outcomes, whether they are trying to communicate in a 
positive way or not, whilst others consistently achieve less placebo-related relief of 
symptoms [23].  This is in keeping with a large body of research in psychotherapy that 
indicates that different practitioners have widely varying abilities to help people improve 
their mental health [24,25]. 
 
Nocebo effects and pain 
Nocebo effects, or ‘negative non-specific effects’, have been observed in many different 
contexts [26]. For example: health-care interventions can sometimes result in idiosyncratic, 
unexpected adverse effects in individual patients [27]; sham pills used as ‘controls’ in RCTs 
often cause adverse side-effects [28]; and population-based interventions, such as the 
introduction of mobile phones or wind farms, can result in widespread, unexplained illness 
[29,30].  These are examples of what have been called ‘adverse outcomes resulting from 
negative expectations’ [31] because most investigators have assumed that expectations are 
responsible for the effects observed.  However, Greville-Harris and Dieppe have recently 
argued for the need to look more widely for explanations of negative outcomes, which can 
arise from several different contextual, environmental and interactional factors [10]. 
It is difficult to undertake nocebo experiments, because, by definition, one is trying to make 
people feel worse, not better.  However, some elegant pain experiments have been carried out 
in the laboratory of Fabrizio Benedetti and colleagues [11,12,32].  They demonstrate that 
negative expectations can make pain more severe, and that anxiety makes a nocebo pain 
response more likely [12].  Although the majority of data available about pain and nocebo 
effects refers to acute rather than chronic pain, we have no reason to believe that nocebo 
effects cannot make OA pain worse; indeed, as outlined below, we believe it highly likely 
that this is a common, important phenomenon in routine health-care. 
 
Placebo research and the mechanisms responsible for placebo and nocebo effects 
Research has been dominated by two disciplines – psychology and neurophysiology – both 
have concentrated on the brain of the patient, and worked more on placebo than nocebo. 
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Psychologists pursue two main theories – conditioning and expectation [1,32] – and there is 
good evidence to support them both.  For example, experiments with cyclosporine A show 
that immunosuppression can be conditioned in both animals and humans [33, 34].  There are 
also numerous examples of experimental or observational work which indicates that positive 
and negative expectations can have a large influence on outcomes after the use of an 
intervention [1,32].  Psychologists have also investigated the influence of the patient’s 
personality on their response to placebo [35]. 
Neurophysiology and functional neuro-imaging show what happens in the brain when a 
placebo response is activated [36,37,38].  For example, work on Parkinson’s disease has 
proved instructive, as placebos can result in huge improvements in patient function, 
associated with demonstrable changes in brain images, mediated by changes in dopamine 
release [40]. In the field of pain, it has been shown that placebo pain relief is blocked by 
naloxone, suggesting that it is mediated by endorphin release, and that reduced 
cholecystokinin release is important, in addition to activation of reward centres through 
dopamine release [11,32,39,40,41].  The activation of descending inhibitory pain pathways 
appears to occur, and it has been suggested that the functional network architecture of the 
brain [42], as well as genetics [43] can predict placebo responsiveness. 
Moerman has tried to rename the placebo response the ‘meaning response’ as his work 
suggests that the key mediator of the effects is the meaning of the whole intervention to the 
individual [44,45].  Recently, LeBlanc has tried to marry together the different psychological 
and physiological theories (expectation, conditioning and meaning) through his ‘full 
correspondence theory’ which points out that our memories result in certain environmental 
cues activating emotional responses that translate into physiological changes in the body [46].  
Another interesting strand of research concerns the alignment of beliefs and rituals between 
the HCP and their client; this work indicates that a shared belief and involvement in a given 
ritual or mechanistic belief will enhance a placebo response [47]. 
Neurobiological mechanisms within patients’ brains, thought to be important in placebo, 
were reviewed in this journal recently [48] and have been extensively reviewed by other 
authors [1,32].  But we believe that these avenues of research – which concentrate on the 
patient alone – do not address the most important mediators of placebo and nocebo effects.  
The practitioner-patient interaction is the focal point of all medical transactions.  In our view, 
the behaviours of the practitioner, and the nature and quality of the transactions that occur 
between HCP and client, as well as the environment in which these transactions take place, 
are the keys to placebo/nocebo induction.   
 
Transactions between health-care professionals and their clients 
Health-care revolves around the interaction between a health-care professional (HCP) and 
client.  This is a particular form of human interaction played out within certain unwritten 
rules: the person in the role of HCP usually has the dominant power; they are seen as the 
person with superior knowledge and the ability to deal with health problems, while the 
‘patient’ is expected to play the role of a supplicant, sick person.  Certain rituals are expected 
to take place, such as taking the history, and the physical examination.  Numerous symbols of 
medical power, such as the stethoscope, are generally on display, and the HCP may be 
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wearing a distinctive uniform.  It is usual for the patient to be anxious when ushered into the 
room in which these rituals take place, and little attention is paid to the ways in which the 
environment (the colours, decorations, smell, and ‘feel’ of the consulting room, for example) 
might affect the transaction. 
Some placebo research has concentrated on the HCP rather than the patient alone (the work 
on consultation style quoted above, for example), and on concepts surrounding their 
interaction.  Carl Rogers’ theory about the importance of clinical behaviours has been 
particularly influential in psychiatry [49,50].  Rogers suggested that if a clinician was to be an 
effective ‘healer’ (which we interpret as meaning someone who induces a good placebo 
effect) they must be genuine (expressing their true feelings), display positive regard (caring 
for and valuing the client), be empathic (communicate understanding) and show 
unconditional regard (a positive attitude should be maintained whatever the client says or 
does).  Another HCP-related factor that has been stressed in the healing literature is that of 
‘presence’ (being there for another person).  A framework of four levels of therapeutic 
presence has been described (presence, partial presence, full presence, and transcendental 
presence) [51,52].  Empathy - has been introduced into training in some medical schools, 
however, in this context the human interaction of the consultation is often reduced to a script.  
As a result, the words spoken are no longer ‘genuine’ because they are not the clinician’s 
own and do not arise from the current consultation. We argue this process of de-
contextualisation reduces effectiveness [53]. 
We tend to ignore the time element: for example, we are usually concerned with a single 
moment or mode of HCP/patient interaction but the effectiveness of a treatment is shaped by 
other contexts such as the patients’ home or work. A typical prescription of a drug is not just 
about a pharmaceutical, but about a ritual that the patient enacts three times daily until the 
course of drugs is complete. The patient’s interaction with the context for the treatment is 
characterised by a process of interpretation: a process by which they make their experiences 
meaningful. As both time and context shift, so does the patient’s response. 
 
What can change as a result of placebo or nocebo effects in OA, and how might we use 
placebo experiments to aid our understanding of the condition? 
As outlined above, we know that placebo and nocebo effects in OA can change pain, 
stiffness, anxiety and depression.  We also know that giving sham interventions can alter 
immune function and autonomic nervous system activity, but what about other changes that 
might occur, in health-related behaviours for example?   Changes in activity or medication 
use resulting from a client-practitioner interaction could be of great long-term significance to 
symptoms, long term outcomes and general health.  Table 1 summarises what we regard as 
the likely and unlikely changes that occur in people with OA. 
 
TABLE: What might change in people with OA as a result of placebo/nocebo effects: 
LIKELY 
 Symptom perception, such as an increase or decrease in pain severity, or altered mood 
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 Physiology, such as alterations in autonomic nervous system activity 
 Changes in health-related behaviours, such as improved self-management 
LESS LIKELY 
 Changes in pathophysiology, such as altered amounts of inflammation in the joints 
UNLIKELY 
 Changes in joint structure 
 
We believe that this should be investigated, and that we can use sham interventions to help us 
understand diseases better – in other words we recommend the use of placebo as an 
investigative tool in OA research. 
Recently ‘open’ placebo studies, in which the recipient is told that the tablets they are being 
given have no active ingredient that should make any difference, have been successfully 
carried out [54], and the participants’ symptoms have improved, indicating that we could give 
people with OA a placebo without deception, and study their responses (both positive and 
negative) using a variety of clinical, biochemical and imaging outcome measures, in order to 
help us understand the disease, as well as the illness. 
The relationship between pathological changes, biomarkers, and symptoms in OA is unclear 
[55].  For example: why is one damaged joint painful and another not, and why is the 
symptom experience so variable?  By carefully examining which symptoms improve (or get 
worse) in response to placebo and which do not, which biomarkers change, and what 
structural change we might observe, we could answer such questions in a totally safe, ethical 
manner, and we could explore the extent to which other outcomes, such as health behaviours, 
are affected. 
 
PART 2.  A DIFFERENT APPROACHES TO THE ‘PLACEBO PROBLEM’ 
Methodology: 
Methodological problems abound.  One is the paucity of theoretical frameworks applied.  The 
main theories used have been patient conditioning and expectation, each of which centres on 
the response of the ‘receiver’ of the intervention.  We believe that the ‘giver’ and the 
interactions between the giver (HCP) and receiver (patient or client) are more important.  A 
number of theories of human interactions are available, and we have tested one of them 
(validation/invalidation), as outlined below. 
The experimental approaches used are also problematic.  Most data on placebo and nocebo 
effects comes from experiments (including trials) in which sham interventions are used, but 
fully informed consent is generally required, which alters expectations, and expectation is 
thought to be one of the main factors mediating these responses.  It has been argued that 
consent can induce a nocebo effect in some people [56].  Trials and experiments take place in 
artificial contexts and involve patient-practitioner interactions that may affect outcomes, and 
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are predicated on a linear cause and effect, biomedical model, that does not take account of 
complexity [57]. 
Many of these problems are, of course, recognised, and there are many different designs 
available that get round some of them [57,58,59].  For example, the modified Zelen design 
may avoid the need for consent [60], and a wait-list design can reduce the need for patient-
provider interactions in a control group [61].  Novel trial designs are one approach, but we 
believe that more radical solutions are needed, with the use of multi-disciplinary approaches, 
moving away for the reductionist scientific paradigm, and linear causal pathways, to a whole 
systems approach, concentrating on the contexts in which health care is delivered. 
In the remainder of this article we summarise two approaches that we are taking, which put 
the emphasis on practitioner-client interactions. 
 
The importance of validation and social safety 
We have investigated the importance of one communication theory [62] and one 
neurophysiological theory concerned with social interaction and safety [63-66] in relation to 
placebo and nocebo [67]. 
We used Linehan’s therapeutic construct of validation/invalidation to try to understand the 
role of ‘feeling heard and understood’ to placebo/nocebo effects [62]. Validation is a 
communication strategy used to convey acceptance and understanding to another person 
about their thoughts, feelings desires or behaviours [68]. Invalidation is the opposite, i.e. 
communicating non-acceptance or a lack of understanding to another.  Fruzzetti [69] 
developed a comprehensive framework for delivering and measuring validating and 
invalidating behaviours during person-to-person interactions; validating feedback includes 
active listening, clarifying what the other person has said, or normalising their behaviours. 
Invalidating feedback includes actions such as ignoring or dismissing another person, 
pathologizing their behaviours or insisting on what they should think, feel or do.  
Building on Shenk and Fruzzetti’s experimental work [70], we randomly assigned healthy 
participants to receive validating (understanding), invalidating (non-understanding) or no 
feedback after they completed a series of stressful maths tasks. Invalidated participants 
reported significantly higher levels of negative mood, lower levels of perceived safety, were 
less likely to agree to take part in the study again, and showed higher levels of physiological 
arousal (indexed by increased heart rate and shorter pre-ejection period) than participants in 
the other two groups [26, 67]. This suggests the potentially detrimental and powerful effects 
of non-understanding (invalidating) communication. 
We believe that an important mediator of these powerful negative effects is how safe we feel 
in our social environment. According to Porges’ evolutionary-based polyvagal theory [63-66] 
when we perceive our environment as safe we engage the ‘smart’ vagus (the myelinated 
pathways of the vagal nerve). This ‘smart’ vagal pathway slows our heart rate and decreases 
autonomic arousal levels, by facilitating a calm visceral state. Because of the connection (via 
the vagus) between the heart and the striated muscles of the head and face, the ‘smart’ vagus 
also allows us to engage with our social world; to listen and express more effectively. In 
contrast, when we perceive the environment as threatening, the ‘smart’ vagus is down-
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regulated and instead we engage our sympathetic nervous system. This increases our heart 
rate, down-regulates the striated muscles of the face and head, and results in a hampered 
ability to engage socially.  
Our experimental and qualitative research [10,67,71] suggests that it is important that the 
patient feels listened to, understood and safe in their environment. If the client feels 
invalidated, and perceives the environment as threatening, this may have detrimental effects. 
 
A ‘trans-disciplinary, whole-systems approach to investigating practitioner-client 
interactions 
We believe that we need to move from a reductionist to a systemic view in two ways; first, to 
recognise that context effects are interdependent and therefore to reduce the consultation to 
isolated elements removed from time and context, is unhelpful. Second, that practice-led 
research outside the fields of medicine and psychology (drama, performance and religious 
studies, for example) have methods of research and analysis which, although unfamiliar to 
medicine, offer rich potential to help us understand what is effective, and generalizable, and 
what can only be understood in an individual encounter.  
We see the clinical encounter as a ritualistic performance.  Our collaboration draws on the 
discipline of Performance Studies which is concerned with how material culture and the 
stories we tell ourselves about our lives, shape our embodied experiences, and determines 
how we each interpret encounters (that appear the same) very differently. For example, a play 
like Hamlet is repeatedly performed using the same script, but no two performances are ever 
the same, even if done by the same company on the same day. The performance blueprint – 
the script – remains the same, as do the settings and the costume, but its subtle interpretation 
is a matter of individual and collective interaction and experience. And while different 
consultations may appear very similar, conducted on the same day, in the same room, by the 
same HCP, the interaction of ritualised performance produces different experiences and 
outcomes. 
Shakespeare said, ‘All the world’s a stage’. People who make theatre analyse the 
performance of everyday life in order to reproduce it and make it effective for its audience. If, 
as men and women, we are merely players (actors) then to create everyday life on stage is to 
understand complex systems of culturally situated processes of communication and 
interpretation. Performance specialists shape these systems in order to produce an effective 
outcome. The discipline draws on two thousand years of scholarship, and a rich tradition of 
theory, enabling engagement in deep-listening with audiences to shape responses with 
profound empathy. This deep-listening is not only aural but also spatial and embodied.  
Actors are trained to be reflexive about their work, to take their physical and emotional care 
seriously, to prepare before every encounter, and to learn through experience.  We want to 
use such work to understand how the HCP in context creates a placebo response. 
But how do we establish what the key processes are, come to understand what works, for 
whom and in what circumstances?  And, perhaps more difficult, make that understanding 
useful to HCPS whose world-view is shaped by biomedical thinking?  We can begin with 
three assumptions: first - humans are complex bio-cultural entities, second - our body's innate 
10 
 
healing (placebo) response can be shaped by contextualised human interactions, third - an 
understanding of ‘culture’ is important. 
There is commonality between medicine and performance: as practitioners (HCPs, actors, 
directors) we recognise that both performance and medicine depend on our practice.  In some 
of the placebo literature the importance of rituals within the clinical encounter have been 
stressed [72,73], and the importance of social interaction is recognised in psychology [74], 
but such work and thinking is still embedded in a scientific, biomedical culture, rather than 
taking a wider perspective.  HCPs are taught to listen, but they get little teaching about the 
importance of non-verbal communication, or about what they might feel in response to 
human distress. Medicine is dominated by facts, figures and machines rather than intuition, 
caring and empathy, and yet placebo research shows us that context, meaning-making and 
caring are central to our well-being and ability to self-heal [1,7,44,72,73]. 
So far, medical research has been unable to explain why interpersonal communication and 
caring is efficacious – how human interactions heal. An engagement with the placebo and 
nocebo effects using a Performance-led approach offers a new way into understanding how 
real-time culturally dependant complex interactions can be shaped to create a positive patient 
experience. 
 
Implications for the management of people with painful OA 
The principles of medical ethics teach us that we should act in the best interests of patients 
and ‘first do no harm’ [75].   This can be achieved by maximising placebo effects (with or 
without the use of an intervention), and avoiding nocebo effects.  Most modern interventions 
are potentially harmful, so we would argue that the more that this can be achieved without 
their use, the better. 
Our review of the placebo and nocebo literature, as well as our experimental work, suggest 
that some physicians are better than others, and that those who can convey a sense of 
optimism (and probably those that improve expectations) are most likely to induce a positive 
response.  But we believe that there are two other key issues that clinicians need to be more 
aware of if they are to activate placebo (healing) effects, and avoid inadvertently doing harm 
(nocebo effects) when seeing patients: 
1. Both the patient and the HCP need to feel ‘safe’ during any healthcare interaction, and 
as far as is possible, have any anxiety alleviated. 
2. The patient’s experiences need validating, and any words or behaviours that might be 
interpreted as invalidating must be avoided. 
Feeling calm and safe: 
Most people feel anxious when consulting a healthcare professional.   Sadly, it is often the 
case that the HCP is also feeling anxious or unsafe during a consultation, as he or she may be 
scared of making a mistake, of missing an important diagnosis, or of not fulfilling the needs 
of the health-care funders, as well as those of the patient.  But when we feel threatened we 
cannot communicate well [63-66].  Perhaps this is why so many patients say that ‘the doctor 
did not understand me’, or ‘I was not listened to properly’, or ‘I did not understand what they 
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said’.  And the nocebo literature indicates that anxiety can make a negative response to the 
non-specific effects surrounding any consultation or prescription more likely, by increasing 
pain perception for example [11,12]. 
Preparing yourself before consulting (actors always go through rigorous ritual of mental and 
physical preparation before going on stage), paying attention to the whole environment, 
finding out how to make any individual feel relatively at ease with you, and shutting out any 
fears of your own, should all be attended to. 
Validating patients, and avoiding invalidation 
Clinicians must try to validate the experiences reported by their patients, and strive to avoid 
invalidation.  Much attention is paid to compassion and empathy in medicine, but you can be 
compassionate and empathic without your patient realising it.  If your understanding and 
acceptance is not perceived by the patient, inadvertent invalidation can ensue, leading to 
potential negative outcomes [71].  Much of the language of OA (such as ‘it is just part of 
getting older’) may be invalidating for some clients. 
How can healthcare professionals avoid invalidating their patients?  We were struck by the 
wisdom of one of the clinicians whom we interviewed for the research outlined above, who 
said that he ‘simply wanted to understand the person and their experiences as best he could’.  
It may be that simple, just being present with someone else and genuinely wanting to 
understand their plight and their point of view.  Maybe that could help us all comply with our 
core ethical principles. 
 
CONCLUSIONS 
Humans are capable of restoring themselves to health, both physiologically and emotionally.  
We believe that what has been termed the placebo response is the ability of human 
interactions and contextual factors to activate what could be called the ‘self-healing 
response’.  In the context of health-care consultations it would appear that a positive  
response is most likely if both the professional and the client feel safe, calm, and lack 
anxiety, and if the experiences of the client are validated by the professional.  The HCP needs 
to achieve ‘focussed attention with good intention’.  This is about caring and love, and is, 
perhaps, the art of medicine [76].  We also believe that a transdisciplinary whole systems 
research approach has to be adopted, rather than a reductionist one, to explore these complex, 
socially constructed, contextual issues [76,77]. 
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